The total size of the ligases enzyme market was about USD 367.4 million in the recent past, and it will power at a rate of 6.2% for reaching USD 631.7 million by 2030, as stated by P&S Intelligence.
 |
| Get the sample pages of this report: https://bit.ly/3KwtAcX |
T4 DNA ligase dominated the industry in the recent past. It will grow at a rate of 6.8% in the years to come.
T4 DNA ligase is extensively put to use in a number of settings for effective and quick litigation, as it has the potential to litigate cohesive-ended and blunt double stranded fragments of DNA, coupled with T/A cloning.
This enzyme is the most elastic ligase and is employed for most of the molecular cloning. The variations of T4 DNA ligase are intended to survive high temperature and high salt.
The Escherichia coli category had the largest revenue share of about 35% in the past, and it will grow at a high pace in the years to come. DNA ligases from E.coli were amongst the first isolated and biochemically suited.
The molecular cloning category dominated the ligases enzyme market and it will generate USD 134.8 million by the end of this decade, growing at a rate of 6.8%.
North America had the largest share in the industry of USD 224.7 million, and it will consolidate its position in the years to come as well, because of an increase in the activities pertaining to research and development for developing ligases as therapeutic agents for cancer and other ailments.
It is because of the increasing prevalence of cancer and other diseases related to old age, the demand for ligases enzyme will continue to grow even more in the near future.
